Abstract
Background: The diagnosis of neuroendocrine neoplasms (NENs) is often delayed. This first UK population-based epidemiological study of NENs compares outcomes with non-NENs to identify any inequalities. Methods: Age-standardised incidence rate (ASR), 1-year overall survival, hazard ratios and standardised mortality rates (SMRs) were calculated for all malignant NENs diagnosed 2013–2015 from UK national Public Health records. Comparison with non-NENs assessed 1-year overall survival (1YS) and association between diagnosis at stage IV and morphology. Results: A total of 15,222 NENs were identified, with an ASR (2013–2015 combined) of 8.6 per 100,000 (95% CI 8.5–8.7); 4.6 per 100 000 (95% CI, 4.5–4.7) for gastro-entero-pancreatic (GEP) NENs. The 1YS was 75% (95% CI, 73.9–75.4) varying significantly by sex. Site and morphology were prognostic. NENs (predominantly small cell carcinomas) in the oesophagus, bladder, prostate, and female reproductive organs had a poorer outcome and were three times more likely to be diagnosed at stage IV than non-NENs. Conclusion: Advanced stage at diagnosis with significantly poorer outcomes of some NENs compared with non-NENs at the same anatomical site, highlight the need for improved access to specialist services and targeted service improvement.
| Original language | English |
|---|---|
| Pages (from-to) | 966-972 |
| Number of pages | 7 |
| Journal | British Journal of Cancer |
| Volume | 121 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 26 2019 |
| Externally published | Yes |
Funding
Funding: This project was funded by the NET Patient Foundation. 1Neuroendocrine Tumour Patients Foundation, Leamington Spa, UK; 2National Cancer Registration and Analysis Service, Public Health England, Birmingham, UK; 3Department of Gastroenterology, King’s College Hospital, London, UK; 4ENETS Centre of Excellence, Neuroendocrine Tumour Unit, King’s College Hospital, London, UK; 5National Cancer Registration and Analysis Service, Public Health England, Cambridge, UK; 6ENETS Centre of Excellence, Oxford University Hospitals Trust, Oxford, UK; 7Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; 8Department of Gastroenterology, University Hospital of Wales, Cardiff & Vale University Hospital Board, Cardiff, UK; 9Department of Hepatobiliary and Pancreatic Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK; 10Department of Cellular Pathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; 11Beatson Oncology Centre, Gartnavel General Hospital, Glasgow, UK; 12Northern Ireland Cancer Registry, Centre for Public Health, Queen’s University Belfast, Belfast, UK; 13Information Services Division, NHS National Services Scotland, Edinburgh, UK and 14Welsh Cancer Intelligence & Surveillance Unit, Public Health Wales, Cardiff, UK Correspondence: Tracey S. E. Genus ([email protected])